less pronounced when infection was performed with HIV-1 carrying VSV G protein. 23
Interestingly, a CRISPR/Cas9 knockout screen of interferon- stimulated genes in U87-MG cells 24 revealed that the interferon induced transmembrane proteins 2 and 3 (IFITM2 and IFITM3) 25 inhibited VSV G pseudotyped HIV-1 much more strongly than the rest of genes tested, including 26
MxB. Therefore, our results demonstrate the importance of MxB in interferon- mediated 27 inhibition of HIV-1 infection, which however can be underestimated if infection is performed 28 with VSV G protein pseudotyped HIV-1, due to the high sensitivity of VSV G mediated 29 infection to the inhibition by IFITM proteins. 30
Importance. Results of this study has reconciled the controversial reports regarding the anti-31
HIV-1 function of interferon- induced MxB protein. In addition to the different cell types that 32 may have contributed to the different observations, our data also suggest that VSV G protein 33 pseudotyped HIV-1 is much less inhibited by interferon- induced MxB than HIV-1 itself. Our 34
Introduction 38
HIV-1 infection is inhibited by type I interferon (IFN) (reviewed in (1)). Several genes that are 39 of ISGs (36). Therefore, depletion of STAT1 is expected to block IFN signaling transduction 107 and prevent the expression of ISGs. Results of western blotting of the generated cell lines 108
showed that both MxB gRNAs efficiently depleted the expression of MxB upon IFN2b 109 stimulation, but did not affect the expression of STAT1, suggesting that MxB knockout does not 110 exert a general effect on cellular response to IFN stimulation ( Figure 1B ). The STAT1 gRNA 111 depleted STAT1 expression that was enhanced by IFN2b, and dramatically reduced MxB 112 expression, which confirmed the impaired IFN response due to STAT1 depletion ( Figure 1B) . 113
As HT1080 cells do not express HIV-1 receptors CD4 and CXCR4/CCR5, we challenged these 114 cells with VSV G pseudotyped HIV-1. Two doses of IFN2b, 500 U/ml and 1000 U/ml, were 115 used to treat HT1080 cells prior to exposure to HIV-1/VSV G. HIV-1 infectivity was determined 116
by infecting the TZM-bl indicator cells (37). IFN2b treatment decreased HIV-1 infection in 117
control cells to 15% (500 U/ml IFN2b) and 6% (1000 U/ml IFN2b) compared to infection 118 without IFN2b treatment ( Figure 1C ). When STAT1 was depleted, HIV-1 infection, in the 119 presence of 1000 U/ml IFN2b, rose from 6% to 40%, indicating a significant loss of IFN2b 120 inhibition ( Figure 1C ). In contrast, IFN2b diminished HIV-1 infection in MxB knockout cells 121 as strongly as in the control cells ( Figure 1C ), which suggests that in HT1080 cells, IFN2b-122 induced MxB does not contribute to the maximal inhibition of VSV G pseudotyped HIV-1 by 123
IFN2b, in agreement with the results by Opp et al (33) . by IFN2b-induced MxB. We chose to knockout MxB in a CD4+ T cell line SupT1 (Figure 2A ) 130 and then, compared the response of HIV-1 to IFN2b treatment in the control and the MxB 131 knockout SupT1 cell lines. We also depleted STAT1 using Cas9/gRNA, and observed that 132 depletion of STAT1, which impairs cellular response to IFN, restored HIV-1 infection under 133
IFN2b treatment from 10% in the control cells to 60% in STAT1 knockout cells ( Figure 2B) . 134
Depletion of MxB by either gRNA1 or gRNA2 elevated HIV-1 infection in the presence of 135
IFN2b from 10% to 40% ( Figure 2B ), which indicates a marked attenuation of IFN2b-136 mediated HIV-1 inhibition as a result of MxB knockout. Interestingly, when the infection was 137 performed with HIV-1 carrying the VSV G protein, although depletion of STAT1 still effectively 138 rescued HIV-1 infection, knockout of MxB increased HIV-1 infection from 10% to only 20%, 139 which is significantly lower than the 40% restoration when infection was performed with HIV-1 140 itself ( Figure 2B ). These results suggest that MxB plays a major role in IFN-mediated 141 inhibition of HIV-1 in T cells. This inhibitory role of MxB becomes less pronounced against 142 HIV-1 that is pseudotyped with VSV G protein.
144
We further investigated the anti-HIV-1 activity of MxB in U87 cells, a human glioblastoma cell 145 line. When MxB was knocked out in U87/CD4/CXCR4 cells ( Figure 2C ), HIV-1 infection in the 146 presence of IFN2b rose from 10% (control cells) to 40% (MxB gRNA1) and 30% (MxB 147 gRNA2), an increase similar to that when STAT1 was knocked out ( Figure 2D ). However, 148 marginal increases were observed in MxB knockout U87/CD4/CXCR4 cells when infection was 149 performed with HIV-1 carrying VSV G, in contrast to an increase from 5% (control cells) to 40% 150 as a result of STAT1 knockout. Similar results were obtained when MxB was knocked out in 151 on July 15, 2018 by UNIV OF CALIF SAN DIEGO http://jvi.asm.org/ Downloaded from U87/CD4/CCR5 cells, and infections were performed with either the R5-tropic HIV-1 strain 152 AD8-1 or AD8-1 carrying VSV G protein (Figure 2E and 2F) . These data further demonstrate a 153 strong inhibition of HIV-1 by IFN-induced MxB, but this inhibition is weakened against VSV 154 G-pseudotyped HIV-1. 155
156
The MxB-resistant capsid mutation H87Q is less inhibited by IFN2b. Mutations in HIV-1 157 capsid mediate resistance to MxB (6-8). We therefore chose to test two such capsid mutations, 158 H87Q and G208A (22, 30) , for their ability to resist IFN2b inhibition. The results showed that 159 the G208A mutant was inhibited by IFN2b in SupT1 cells to similar degrees as the wild type 160 HIV-1 ( Figure 2G ). In contrast, IFN2b decreased the infection of the H87Q mutant to only 40% 161 of that without exposure to IFN2b, which is significantly higher than the 15% observed for 162 wild type HIV-1 ( Figure 2G Figure 5A and 5B). We also performed western blotting to 196 measure the level of endogenous MxB in SupT1 cells upon treatment with IFN2b (500 U/ml), 197 and found that its level was equivalent to the MxB amount that was induced by doxycycline of 5 198 ng/ml to 10 ng/ml in the MxB SupT1 cell line ( Figure 5C ). We then measured the levels of 199 infectious HIV-1 particles that were produced by the infected SupT1 cells. Doxycycline did not 200 markedly affect HIV-1 production from control SupT1 cells that did not express exogenous MxB 201 ( Figure 5D ). The doxycycline-induced MxB inhibited both HIV-1 NL4-3 and HIV-1 NL4-3 202 carrying VSV G to similar degrees, across all doxycycline concentrations tested ( Figure 5D ). 203
The inhibition of HIV-1 by exogenous MxB expression was slightly greater than inhibition of 204 HIV-1 carrying VSV G, but the differences were not significant. These data suggest that MxB, reduces this inhibition, we were interested in knowing which IFN induced protein(s) play the 211 major inhibitory role. To this end, we designed gRNAs to target 53 ISGs which were reported to 212 be upregulated by IFN in U87-MG cells by more than 3-fold (8). In order to achieve efficient 213 knockout, three gRNAs were designed for each ISG (Table S1) with 10% fetal bovine serum (FBS) (Invitrogen), 50 U/ml penicillin, and 50 g/ml streptomycin 315 (Invitrogen). SupT1 cells were grown in RPMI160 medium supplemented with 10% FBS, 50 316 U/ml penicillin, and 50 g/ml streptomycin (Invitrogen). TZM-bl is an HIV indicator cell line 317 that carries the HIV-1 LTR-luc expression cassette, which responds to the transactivation by 318 HIV-1 Tat (37). HEK293T and HT1080 were purchased from ATCC. U87 cell lines were 319
obtained from NIH AIDS Reagent Program. Transfection of HEK293T cells was conducted with 320
Lipofectamine (Invitrogen) in accordance with the manufacturer's instructions. 321 322
Generating MxB knockout cell lines. Lentivirus particles were produced through transfecting 323
HEK293T cells using plasmid DNA clones LentiCRISPRv2 (expressing sgRNA targeting MxB), 324 psPAX2 (expressing Gag and Gag-Pol), and pVSV-G, as described in (39). Next, HT1080, 325
SupT1 and U87 cells were infected with these lentiviruses, followed by puromycin selection to 326 generate stable cell lines. The control cell line was created using the LentiCRISPRv2 vector that 327 does not express sgRNA. MxB knockout efficiency was determined by western blotting, 328 examining levels of MxB in the created cell lines with IFN2b (500 U/ml, Sigma) to induce 329 MxB expression for 24 hours. The anti-MxB antibodies were generated as we previously 330 described (7). The sequences of MxB sgRNAs are, sgRNA1: 5'-331 TGTGGTGGCACTGTGCCGAA-3', sgRNA2: 5'-GTTCCGGTAGCTGATCCTTC-3'. The 332 STAT1 knockout cell lines were generated using the same method. The sequence of STAT1 333 sgRNA is 5'-GCAGCTTGACTCAAAATTCC-3'. 
